Abstract
Elevated serum chromogranin A (CgA) levels have been detected in patients with prostate cancer who have developed resistance to hormonal therapy. We would like to re‐examine these cases by using serial specimens to determine whether such elevated levels are also detectable in prostate cancer patients not undergoing hormonal therapy.
Serum CgA was measured in both random and serial specimens from prostate cancer patients with and without undergoing hormonal therapy. We found that serum CgA levels became elevated much earlier than did the levels of serum PSA in approximately one‐third of prostate cancer patients developing resistance to hormonal therapy. On the other hand, serum CgA levels became elevated at later, more advanced stages of the disease in patients not undergoing hormonal therapy. Elevated serum CgA levels were usually detected in specimens containing highly elevated PSA. The early rise of serum CgA levels provides an early signal allowing a change of therapy to be made before the disease progresses to a fatal stage. Drugs targeting neuroendocrine cells should be considered for prostate cancer patients with elevated serum CgA levels. J. Clin. Lab. Anal. 13:308–311, 1999. © 1999 Wiley‐Liss, Inc.
Keywords: neuroendocrine cells, hormonal resistance
REFERENCES
- 1. Deftos LJ. Chromogranin A—its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991;12:181–186. Medline [DOI] [PubMed] [Google Scholar]
- 2. Angelsen A, Syversen U, Haugen OA, et al. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1–6. Medline [DOI] [PubMed] [Google Scholar]
- 3. Di Sant‐Agnese P, Cockett ATK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357–361. Medline [DOI] [PubMed] [Google Scholar]
- 4. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr, Cathepsin D. Chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109–2119. Medline [PubMed] [Google Scholar]
- 5. Kadmon D, Thompson TC, Lynch GR, Sardino PT. Elevated plasma chromogranin‐A concentrations in prostatic carcinoma. J Urol 1991;146:358–361. Medline [DOI] [PubMed] [Google Scholar]
- 6. Di Sant‐Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: An update. Prostate Suppl 1998;8:74–79. [PubMed] [Google Scholar]
- 7. Wu T‐L, Chang P‐Y, Tsao K‐C, Sun C‐F, Wu JT. Development of a microplate assay for serum chromogranin A (CgA): Establishment of normal reference values and detection of elevated CgA in malignant diseases. J Clin Lab Anal 1999;13:312–319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Kumra N, Hoshi S, Takahashi M, et al. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157:565–568. Medline [PubMed] [Google Scholar]
- 9. Deftos LJ, Abrahamsson P‐A. Granins and prostate cancer. Urology 1998;51(Suppl 5A):141–145. Medline [DOI] [PubMed] [Google Scholar]
- 10. Wu JT. Measurement of AFP and its lectin reactive isoforms in liver diseases and various malignancies. Ann Clin Lab Sci 1990;20:98–105. Medline [PubMed] [Google Scholar]
- 11. Brown JA, Roberts CS. Elevated serum alpha‐fetoprotein levels in primary gallbladder carcinoma without hepatic involvement. Cancer 1992;70:1838–1843. Medline [DOI] [PubMed] [Google Scholar]
- 12. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptro gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314–319. Medline [PubMed] [Google Scholar]
- 13. Raffo AJ, Periman H, Chen M‐W, Day ML, Streitman JS, Buttyan R. Overexpression of bcl‐2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438–4445. Medline [PubMed] [Google Scholar]
- 14. Aprikian AG, Cordoncardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:395–3965. [DOI] [PubMed] [Google Scholar]